Headquartered in Pleasanton, California, 10x Genomics, Inc. (founded in 2012 and known as 10X Technologies, Inc. until November 2014) is a prominent life science technology company. The firm specializes in creating and distributing sophisticated instrumentation, essential consumables, and software designed for in-depth analysis of biological systems. Its market presence extends globally, covering North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company's offerings feature Chromium and Chromium Connect instruments, supported by indispensable items such as microfluidic chips, slides, and reagents. A significant portion of their portfolio focuses on single-cell solutions, leveraging their Chromium platforms. These allow for precise measurement of gene activity at the individual cell level (single cell gene expression), detailed assessment of immune cell function and their targets (single cell immune profiling), exploration of DNA's physical organization and epigenetic modifications (single cell Assay for Transposase Accessible Chromatin - ATAC), and the concurrent quantification of both genetic activity and epigenetic programming across tens of thousands of cells in a single experiment (single cell multiome ATAC + gene expression). Additionally, 10x Genomics offers the Visium spatial gene expression solution, which maps gene activity patterns within specific tissue sections and can also facilitate co-detection of gene expression and proteins when paired with immunofluorescence. Their varied customer base includes academic, governmental, biopharmaceutical, and biotechnology organizations, among others.
前收盤價
US$76.10
−US$4.56 · -5.65%
盤前
US$72.39
−US$3.71 · -4.88%
10月8日 上午8:21 ET
盤中時間採用ET。市場資料可能有所延遲。
Headquartered in Pleasanton, California, 10x Genomics, Inc. (founded in 2012 and known as 10X Technologies, Inc. until November 2014) is a prominent life science technology company. The firm specializes in creating and distributing sophisticated instrumentation, essential consumables, and software designed for in-depth analysis of biological systems. Its market presence extends globally, covering North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company's offerings feature Chromium and Chromium Connect instruments, supported by indispensable items such as microfluidic chips, slides, and reagents. A significant portion of their portfolio focuses on single-cell solutions, leveraging their Chromium platforms. These allow for precise measurement of gene activity at the individual cell level (single cell gene expression), detailed assessment of immune cell function and their targets (single cell immune profiling), exploration of DNA's physical organization and epigenetic modifications (single cell Assay for Transposase Accessible Chromatin - ATAC), and the concurrent quantification of both genetic activity and epigenetic programming across tens of thousands of cells in a single experiment (single cell multiome ATAC + gene expression). Additionally, 10x Genomics offers the Visium spatial gene expression solution, which maps gene activity patterns within specific tissue sections and can also facilitate co-detection of gene expression and proteins when paired with immunofluorescence. Their varied customer base includes academic, governmental, biopharmaceutical, and biotechnology organizations, among others.
日內區間
目前US$76.10
52週區間
目前US$76.10
盤中時間採用ET。市場資料可能有所延遲。
Headquartered in Pleasanton, California, 10x Genomics, Inc. (founded in 2012 and known as 10X Technologies, Inc. until November 2014) is a prominent life science technology company. The firm specializes in creating and distributing sophisticated instrumentation, essential consumables, and software designed for in-depth analysis of biological systems. Its market presence extends globally, covering North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company's offerings feature Chromium and Chromium Connect instruments, supported by indispensable items such as microfluidic chips, slides, and reagents. A significant portion of their portfolio focuses on single-cell solutions, leveraging their Chromium platforms. These allow for precise measurement of gene activity at the individual cell level (single cell gene expression), detailed assessment of immune cell function and their targets (single cell immune profiling), exploration of DNA's physical organization and epigenetic modifications (single cell Assay for Transposase Accessible Chromatin - ATAC), and the concurrent quantification of both genetic activity and epigenetic programming across tens of thousands of cells in a single experiment (single cell multiome ATAC + gene expression). Additionally, 10x Genomics offers the Visium spatial gene expression solution, which maps gene activity patterns within specific tissue sections and can also facilitate co-detection of gene expression and proteins when paired with immunofluorescence. Their varied customer base includes academic, governmental, biopharmaceutical, and biotechnology organizations, among others.
日內區間
目前US$76.10
52週區間
目前US$76.10
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目(USD) | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 6.43億 USD | 6.11億 USD | 6.19億 USD | 5.16億 USD | 4.9億 USD |
| 銷貨成本 | 1.99億 USD | 1.96億 USD | 2.09億 USD | 1.2億 USD | 7409.1萬 USD |
| 毛利 | 4.44億 USD | 4.14億 USD | 4.09億 USD | 3.96億 USD | 4.16億 USD |
| 研究與開發 | 2.39億 USD | 2.65億 USD | 2.7億 USD | 2.66億 USD | 2.12億 USD |
| 銷售、一般及管理費用 | 3.16億 USD | 3.44億 USD | 3.43億 USD | 2.98億 USD | 2.58億 USD |
| 營業費用 | 5.55億 USD | 6.09億 USD | 6.75億 USD | 5.64億 USD | 4.69億 USD |
| 利息收入 | 2004.8萬 USD | 1844.8萬 USD | 1690.6萬 USD | 664.7萬 USD | 20.6萬 USD |
| 利息支出 | — | 4000 USD | 3.3萬 USD | 47.6萬 USD | 86.6萬 USD |
| 折舊和攤銷 | 4381.6萬 USD | 4370.8萬 USD | 4361.9萬 USD | 3300.6萬 USD | 2825.4萬 USD |
| 營業利益 | −1.11億 USD | −1.95億 USD | −2.65億 USD | −1.68億 USD | −5291.3萬 USD |
| 淨利 | −4354.4萬 USD | −1.83億 USD | −2.55億 USD | −1.66億 USD | −5822.3萬 USD |
公司資料更新於 2026年10月8日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動,並非 GoAI 建議。
平均目標
US$74.30
下跌空間 2.37%| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2006年7月17日 | 1:2 | — | — |
已生效 2006年7月17日
1:2
報告持有此股票曝險的交易所交易基金。
ARK Innovation ETFARKK3.27億2.95%55.62億 USD0.75%US$88.30-2.42%
iShares Russell 2000 ETFIWM2.47億0.31%785.63億 USD0.19%US$277.7-1.29%
Vanguard Morningstar Total Stock Market ETFVTI2.2億0.01%2.3兆 USD0.03%US$381.03-0.40%
ARK Genomic Revolution ETFARKG1.89億8.97%15.57億 USD0.75%US$50.14-3.11%
Vanguard Morningstar Small-Cap ETFVB1.6億0.09%1853億 USD0.03%US$286.98-1.41%
Vanguard Morningstar Small-Cap Growth ETFVBK9157.53萬0.20%447億 USD0.05%US$342.24-1.50%
iShares Russell 2000 Growth ETFIWO8851.12萬0.62%142.49億 USD0.24%US$355.37-1.43%
Vanguard Extended Market ETFVXF8481.65萬0.09%954億 USD0.05%US$233.49-1.56%
ARK Innovation ETFARKK
iShares Russell 2000 ETFIWM
Vanguard Morningstar Total Stock Market ETFVTI
ARK Genomic Revolution ETFARKG
Vanguard Morningstar Small-Cap ETFVB
Vanguard Morningstar Small-Cap Growth ETFVBK
iShares Russell 2000 Growth ETFIWO
Vanguard Extended Market ETFVXFAI 生成內容及延遲市場資料僅供資訊與教育用途,不構成投資建議。